Wall Street brokerages expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report sales of $136.12 million for the current quarter, Zacks reports. Eight analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $142.00 million and the lowest estimate coming in at $127.10 million. Neurocrine Biosciences reported sales of $71.09 million in the same quarter last year, which indicates a positive year over year growth rate of 91.5%. The company is scheduled to announce its next earnings results on Monday, April 29th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full-year sales of $671.48 million for the current fiscal year, with estimates ranging from $630.61 million to $733.66 million. For the next fiscal year, analysts expect that the company will report sales of $967.52 million, with estimates ranging from $903.00 million to $1.02 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. The business had revenue of $131.49 million during the quarter, compared to the consensus estimate of $132.32 million. During the same quarter last year, the company earned $0.07 earnings per share. The company’s quarterly revenue was up 39.1% on a year-over-year basis.
A number of analysts have recently commented on NBIX shares. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Oppenheimer boosted their price target on Neurocrine Biosciences from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 13th. Zacks Investment Research cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 9th. Finally, Bank of America dropped their price target on Neurocrine Biosciences from $124.00 to $117.00 and set a “buy” rating for the company in a research report on Wednesday, February 6th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $102.56.
Shares of Neurocrine Biosciences stock traded down $2.79 on Wednesday, reaching $84.83. 558,912 shares of the stock were exchanged, compared to its average volume of 977,201. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences has a twelve month low of $64.72 and a twelve month high of $126.98. The company has a market capitalization of $7.96 billion, a price-to-earnings ratio of 385.59, a price-to-earnings-growth ratio of 27.34 and a beta of 1.86.
In related news, insider Kyle Gano sold 3,809 shares of the business’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total transaction of $335,649.08. Following the completion of the sale, the insider now directly owns 17,595 shares in the company, valued at $1,550,471.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eiry Roberts sold 1,857 shares of the business’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $84.09, for a total value of $156,155.13. Following the transaction, the insider now directly owns 3,143 shares in the company, valued at approximately $264,294.87. The disclosure for this sale can be found here. Insiders have sold 13,280 shares of company stock valued at $1,163,054 over the last quarter. 4.30% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter worth $32,000. Exane Derivatives boosted its stake in Neurocrine Biosciences by 48,400.0% during the fourth quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after buying an additional 484 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in Neurocrine Biosciences by 54.7% during the third quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after buying an additional 197 shares during the last quarter. Penserra Capital Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter worth $86,000. Finally, Arbor Wealth Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter worth $92,000. 99.82% of the stock is currently owned by institutional investors.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.